Yazen is a technology company.
Yazen provides personalized medical weight loss advice and support, focusing on overall health and well-being through a team of specialists including dietitians and psychologists.
Yazen has raised $24.0M across 2 funding rounds.
Yazen has raised $24.0M in total across 2 funding rounds.
Yazen has raised $24.0M in total across 2 funding rounds.
Yazen's investors include Luminar Ventures.
Yazen is a digital healthcare company that provides medically supervised weight‑loss treatment combining modern medications, personalized lifestyle coaching, and continuous digital follow‑up to treat obesity across several European markets[5][1].
High-Level Overview
Yazen is a digital healthcare provider focused on obesity care that delivers a combined medical and behavioral treatment program through an app and remote clinical team[5][1]. The company pairs licensed physicians with coaches, dietitians, psychologists and trainers to create individualized plans that use evidence‑based medicines plus lifestyle support; it reports over 40,000 patients treated to date and more than 360 tonnes of weight lost across its patient base[1]. Yazen has grown rapidly across Europe—operating in Sweden, Norway, Denmark, the Netherlands, the UK, Germany and Spain—and recently scaled headcount and revenue substantially while being ranked the second fastest‑growing startup in Europe by Sifted’s 2025 list[1][5].
Origin Story
Yazen was founded in 2021 by entrepreneurs with prior experience building digital health services (the founders previously launched services such as MinDoktor and Blodtrycksdoktorn), and it is headquartered in Lund, Sweden[3][5]. The idea emerged from combining clinical obesity expertise with tech‑enabled remote delivery to address long‑term chronic care needs for patients with overweight and obesity; early traction included rapid user growth and clinical scale—reaching tens of thousands of patients within a few years—and expansion into multiple European markets[1][3].
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Yazen has established a differentiated, medically oriented digital obesity clinic and demonstrated rapid scale and measurable outcomes across multiple European countries—making it a leading player in digital obesity care[1][5]. Near term, expect continued geographic expansion, product refinement (deeper care pathways, tighter integration with primary care and payers), and efforts to commercialize relationships with employers and health systems as evidence accumulates. Key trends that will shape Yazen’s trajectory include regulatory stance on obesity medications, reimbursement models for long‑term digital care, and competition from other digital therapeutics and clinic networks integrating GLP‑1 therapies[1][5]. If Yazen sustains clinical outcomes and converts scale into repeatable payer or employer contracts, it could become a standard channel for accessible, long‑term obesity treatment across Europe—fulfilling its stated aim to be Europe’s leading digital obesity care provider[1][5].
Sources: Yazen corporate site and company news; Almaz Capital portfolio description; The Hub company profile[5][2][3][1].
Yazen has raised $24.0M across 2 funding rounds. Most recently, it raised $21.0M Series A in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $21.0M Series A | Luminar Ventures | |
| Aug 1, 2023 | $3.0M Seed | Luminar Ventures |